Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Investment at Fair Value (Tables)

Investment at Fair Value (Tables)

3 Months Ended

Mar. 31, 2015

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis in the accompanying Condensed Consolidated Balance Sheets as of March 31, 2015 and December 31, 2014:

	Fair Value Measurement as of March 31, 2015
($ in thousands)	Level 1		Level 2	Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	20,000	$	$		$	20,000
Mutual funds		5					5
Total marketable securities		20,005					20,005
Long-term investments, at fair value					3,945		3,945
Total	$	20,005	$	$	3,945	$	23,950

	Fair Value Measurement as of December 31, 2014
($ in thousands)	Level 1		Level 2	Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	19,998	$	$		$	19,998
Mutual funds		4					4
Total marketable securities		20,002					20,002
Long-term investments, at fair value					4,160		4,160
Total	$	20,002	$	$	4,160	$	24,162

Schedule of changes in fair value of financial instruments

The table below provides a rollforward of the changes in fair value of Level 3 financial instruments, as of March 31, 2015:

	Fair Value of Investments
	Short-term	Long-term
($ in thousands)	Other	Other		CB Pharma		Total
Balance at December 31, 2014	$	$	250	$	3,910	$	4,160
Purchases
Change in fair value of investment					(215)		(215)
Balance at March 31, 2015	$	$	250	$	3,695	$	3,945